The Translational Genomics Research Institute | Date: 2015-03-25
Embodiments of the invention provide methods of creating clinical models for different forms of metastatic cancer. The methods may include obtaining samples from subjects with metastatic cancer, determining an allelic status of one or more markers in the samples (e.g., creating a molecular profile of the subjects cancer), and using model organisms with subject-derived xenografts for treatment selection.
The Translational Genomics Research Institute | Date: 2015-10-23
The present invention is directed to methods for treating cancer in a subject, such as a cancer of the endocrine system. In some aspects, the method includes administering to the subject one or more of a polo-like kinase 1 inhibitor, a mouse double minute 2 inhibitor, and/or a mitotic catastrophe inducing compound. In other aspects, the method includes measuring an expression level of one or more markers, including caspase 8 and caspase 9, to assess the functionality of the caspase cascade in the subject.
The Translational Genomics Research Institute and Northern Arizona University | Date: 2015-08-06
The Translational Genomics Research Institute | Date: 2014-10-28
The present invention is directed to a method of detecting a genomic rearrangement in a nucleic acid sample with Long Insert Whole Genome Sequencing (LI-WGS). The method may include obtaining a nucleic acid sample and then fragmenting the nucleic acid sample (e.g., via sonication). In particular, the fragmenting may result in the production of a plurality of inserts. Thereafter, the method comprises purifying the plurality of inserts using magnetic beads and then amplifying the purified plurality of inserts. In addition, the method further comprises sequencing the purified and amplified plurality of inserts. In some aspects, the plurality of inserts have a length of between about 800 and about 1,100 base pairs.
The Translational Genomics Research Institute | Date: 2015-03-11
The present invention provides methods and compositions for enhancing working memory impaired in a tau pathological condition associated with AD or Downs syndrome.